-

12:57:35 AM

ALDX Stock News

ALDX - Aldeyra Therapeutics Inc

11/02/21 8:00 AM

Nasdaq : ALDX

clinical trial

Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease

Aldeyra Therapeutics, Inc. today announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled Phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% reproxalap ophthalmic solution, and 78 patients were...

RHEA-AI

neutral

10/28/21 7:00 AM

Nasdaq : ALDX

earnings

Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights

Aldeyra Therapeutics, Inc., a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported recent corporate highlights and financial results for the quarter ended September 30, 2021. ADX-629 represents a first-in-class systems-based therapeutic approach for the potential treatment of...

RHEA-AI

neutral

10/21/21 8:00 AM

Nasdaq : ALDX

conferencesearnings

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights

Aldeyra Therapeutics, Inc. will host a conference call at 8:00 a.m. ET Thursday, October 28, 2021 to report financial results for the quarter ended September 30, 2021 and discuss recent business highlights. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days. Aldeyra Therapeutics is a biotechnology company...

RHEA-AI

neutral

09/09/21 8:00 AM

Nasdaq : ALDX

conferences

Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Aldeyra Therapeutics, Inc., today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research for Oppenheimer& Co. at the virtual Oppenheimer Fall Healthcare Life Sciences& MedTech Summit on Wednesday, September 22, 2021 at...

RHEA-AI

neutral

09/02/21 8:00 AM

Nasdaq : ALDX

conferences

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc., a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:. H.C. Wainwright 23rd Annual Global Investment Conference Date: Monday,...

RHEA-AI

neutral

08/05/21 7:00 AM

Nasdaq : ALDX

earnings

Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highlights.“We continue to make meaningful

RHEA-AI

positive

08/04/21 8:00 AM

Nasdaq : ALDX

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). There are no approved drug treatments for

RHEA-AI

very positive

08/03/21 8:00 AM

Nasdaq : ALDX

conferences

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the BTIG Virtual Biotechnology Conference and the H.C. Wainwright Ophthalmology Virtual

RHEA-AI

neutral

07/20/21 8:00 AM

Nasdaq : ALDX

Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company for ADX-2191 (methotrexate for intravitreal injection) for the treatment of primary vitreoretinal lymphoma (PVRL). There are no

RHEA-AI

very positive

07/01/21 8:00 AM

Nasdaq : ALDX

Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that the company was added to the broad-market Russell 3000 ® Index and the small-cap Russell 2000 ® Index, effective

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next

ALDX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.aldeyra.com
Security nameAldeyra Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees11
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.